

A HMWK Capillary Immunoblotting Assay to Characterise Bradykinin-Mediated Disorders

Abstract ID 116579

Evangelia Pardali¹, Dan Sexton², Grit Zahn³, Anne Lesage⁴

¹Pharvaris B.V., Leiden, The Netherlands; ²Sexton Bio Consulting, LLC, Melrose, MA, US; ³Globalization Partners, Munich, Germany; ⁴GrayMatters Consulting, Schilde, Belgium

Introduction

- Activation of the plasma kallikrein-kinin system (KKS) results in cleavage of high molecular weight kininogen (HMWK) and production of vasodilatory kinins, such as bradykinin (BK).¹
- BK is involved in various physiological and pathological processes, including angioedema (AE).² Differentiating BK-mediated from histamine-mediated AE and assessing the role of BK in the pathogenesis of other conditions, by analysing biomarkers produced upon activation of the KKS remains a challenge due to limitations of current analytical assays.³
- Cleavage of intact (i)HMWK results in generation of BK and cleaved (c)HMWK, which serves as a surrogate marker for BK.
- Establishment of a method to measure levels of i/cHMWK could aid in identifying and studying BK-mediated disorders.


Materials and Methods

- To inhibit *ex vivo* activation of KKS proteases and proteolytic degradation of BK, a protease inhibitor (PI) cocktail was manufactured in a liquid form (Liquid PI).
- Blood samples were collected from healthy volunteers (HV) by Fidelis Research AD (Sofia, Bulgaria) in accordance with the Declaration of Helsinki and approved by The National Bioethics Committee of Medicines and Medical Devices (CNBMDM, protocol no. FRT-19101). All participants provided their written informed consent before enrolment.
- Blood was collected using S-Monovettes (Sarstedt) with a single venipuncture with a 21G x 3/4" Safety-Multifly® needle (Sarstedt), using the aspiration technique. Following venipuncture, a small blood aliquot was collected and discarded.
- Plasma was prepared from tubes containing either Liquid PI or ethylenediaminetetraacetic acid (EDTA) as a control.
- A Simple Western Size (SWS) capillary immunoblotting assay was developed under non-reducing conditions for the detection and analysis of iHMWK and cHMWK using Abcam anti-human HMWK antibody.
- Qualification of the assay was performed using Liquid PI plasma or EDTA plasma from HVs.
- Plasma samples were diluted in kininogen-deficient (KD) plasma in the presence of Liquid PI and analyzed in two replicates at four different dilutions.

Results

- Standard curves were prepared by spiking iHMWK or cHMWK in KD plasma in the presence of Liquid PI.
- For both proteins, the back-calculated concentrations of the standards met qualification criteria (Figure 1).

Figure 1. Standard (SD) curves of iHMWK and cHMWK in KD plasma




	Linearity range of quantification LLOQ - ULOQ	Concentration range accessible in human plasma
i/cHMWK	2 – 20 ng/mL	6 – 140 µg/mL

LLOQ: lower limit of quantification; ULOQ: upper limit of quantification

- To determine accuracy, recombinant iHMWK and cHMWK proteins at three different concentrations were diluted in KD plasma in presence of Liquid PI.
- Analysis of i/cHMWK quality control (QC) samples met qualification criteria for intra- and inter-run accuracy and precision. Accuracy: 80-120% of nominal concentration; Precision: Coefficient of variation (CV) <20% (Figure 2).

Figure 2. Analysis of quality control (QC) samples for iHMWK and cHMWK in KD plasma



QC Sample nominal concentration	Concentration (ng/mL)				Accuracy (%)			
	iHMWK		cHMWK		iHMWK		cHMWK	
	Mean ± SD	CV%	Mean ± SD	CV%	Mean ± SD	CV%	Mean ± SD	CV%
3 ng/mL	3.2 ± 0.3	10.0	3.1 ± 0.5	15.8	107.4 ± 10.7	10.0	104.4 ± 16.5	15.8
10 ng/mL	8.8 ± 1.0	11.7	9.1 ± 1	11.3	98.1 ± 11.5	11.7	101 ± 11.4	11.3
15 ng/mL	15.7 ± 2.4	15.1	17.9 ± 3.4	19.0	87.0 ± 13.2	15.1	99.2 ± 18.8	19.0


Precision: CV% ≤ 20%

High / Medium Accuracy: 80-120%; Precision: CV% ≤ 20%

Results


- Assay parallelism was evaluated in EDTA plasma diluted in KD plasma at four different dilutions, in three independent experiments.
- Final concentration of iHMWK and cHMWK was estimated in each dilution sample.
- iHMWK and cHMWK analysis met parallelism acceptance criteria with CV <20% (Figure 3).

Figure 3. Parallelism for iHMWK and cHMWK in EDTA plasma



- Intra-run precision was analysed in Liquid PI and EDTA control samples at 4 dilutions in duplicates and final i/cHMWK concentrations were calculated.
- Comparable levels of iHMWK and cHMWK were observed in EDTA plasma, indicating activation of KKS system.
- Significantly lower cHMWK levels compared to iHMWK were detected in Liquid PI plasma, suggesting that Liquid PI inhibited unspecific KKS activation and cleavage of iHMWK (Figure 4).
- Acceptable intra-run variability was detected (CV <20%) for both iHMWK and cHMWK in Liquid PI and control EDTA plasma (Figure 4). However, higher variability between different dilutions was observed in EDTA plasma.

Figure 4. iHMWK and cHMWK intra-run variability in Liquid PI and EDTA plasma




Plasma	Dilution	iHMWK (µg/mL)				cHMWK (µg/mL)				
		Value 1	Value 2	Mean ± SD	%CV	Value1	Value2	Mean ± SD	%CV	
Liquid PI	Dil 1	aULLoQ	aULLoQ	n/a	n/a	n/a	8.6	8.7	8.7 ± 0.1	0.5
	Dil 2	aULLoQ	aULLoQ	n/a	n/a	n/a	6.9171	7.2	7.1 ± 0.2	3.0
	Dil 3	82.3	88.3	85.3 ± 4.2	5.0	bULLoQ	bULLoQ	n/a	n/a	
	Dil 4	85.3	83.7	84.5 ± 1.1	1.3	bULLoQ	bULLoQ	n/a	n/a	
EDTA	Dil 1	51.1	49.2	50.1 ± 1.3	2.7	35.1	31.6	33.4 ± 2.5	7.4	
	Dil 2	51.6	49.6	50.6 ± 1.3	2.7	33.1	34.6	33.9 ± 1.1	3.1	
	Dil 3	53.2	55.6	54.4 ± 1.7	3.2	8.5	9.2	8.8 ± 0.5	5.6	
	Dil 4	60.7	56.3	58.5 ± 3.1	5.2	6.9	6.2	6.6 ± 0.5	7.2	

bLLoQ: below lower limit of quantification; aULLoQ: above upper limit of quantification; n/a: not applicable

- Inter-run precision was analysed in Liquid PI and EDTA control samples at 4 dilutions in three independent experiments, and final i/cHMWK concentrations were calculated. (Figure 5).
- Acceptable inter-run variability was observed (CV <20%) for both iHMWK and cHMWK in both Liquid PI plasma and control EDTA plasma (Figure 5).

Figure 5. iHMWK and cHMWK inter-run variability in Liquid PI and EDTA plasma



	iHMWK		cHMWK	
	Mean±SD (µg/mL)	%CV	Mean±SD (µg/mL)	%CV
Liquid PI	87.8 ± 11.4	13.0	8.3 ± 0.9	10.8
EDTA	58.9 ± 10.4	17.7	42.3 ± 7.4	17.6

Conclusions

- Increased KKS activation resulting in cleavage of iHMWK and increased cHMWK levels was observed in EDTA plasma as compared to plasma collected in tubes with Liquid PI.
- Therefore, the PI cocktail was efficacious in inhibiting non-specific activation of KKS and cleavage of iHMWK as compared to EDTA without PI.
- The established qualified i/cHMWK assay can be used to reliably measure KKS biomarkers in human plasma.
- The i/cHMWK capillary immunoblotting assay could become a key tool for identifying, studying, and managing BK-mediated diseases.

References

1. Kaplan AP, et al. Adv Immunol. 2014;121:41-89. 2. Maurer M, et al. Clin Rev Allergy Immunol. 2021;61:40-9. 3. Kaplan AP, et al. Front Med (Lausanne). 2017;4:206.